Bayer’s eager to send its animal health unit to Elanco so it can focus its healthcare efforts on pharmaceuticals. But that US$7.6 billion selloff, like many other recent life sciences deals, has hit an antitrust snag.
The US Federal Trade Commission (FTC) sent Elanco a second request for information about the deal, the Indiana-based veterinary specialist announced on Monday, December 9.
Despite the extra scrutiny, Elanco maintained that the request “was anticipated as part of the regulatory process,” and that it still expects to wrap the deal in mid-2020 as previously announced.
“We continue to work collaboratively with the FTC and other regulators around the world and are progressing as expected,” Jeff Simmons, president and CEO of Elanco, said in a statement.
A “second request” means the FTC’s initial review has raised some potential anti-competition questions, which the agency wants to delve into more deeply. While most deals are allowed through on first look, the FTC has issued a series of second requests to life sciences companies on recent deals.
Roche’s US$4.3 billion takeover of gene therapy biotech Spark Therapeutics still awaits an FTC decision after it unveiled a second request in early June. AbbVie and Allergan’s proposed US$63 billion merger was hit with the same demand in September. And DNA-sequencing giant Illumina’s US$1.2 billion purchase of competitor Pacific Biosciences has also been delayed by that additional antitrust scrutiny.
Full Content: Elanco, Fierce Pharma
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI